January 18, 2017 6:34pm

 

There are possibilities and options but, inadequate perception of emerging risks …

 

My admonition, it’s up to investors to NOT step-up to some of these repetitive and dilutionary financings … choices NEED to be made!

 

In compiling my indication signals, I draw on logic, historical precedents and specific knowledge of the sector as to its practices of lessons learned.  It’s important for investors to identify and determine which indication is actual performance based.

 

Pre-open indication’s tally:  2 hit (ATHX and ONVO) and 3 miss (AGTC, BLCM and HSGX)

Out and about: Pluristem (PSTI) – a quick, small offering with no pricing?

 

Can you afford to miss the insider view … Click here for access and subscribe:  http://www.regmedinvestors.com/create-account      

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 

U.S. stocks closed mixed on Wednesday as investors digested remarks from the top Federal Reserve official, having parsed through a series of corporate earnings and economic data.

The NASDAQ closed UP +16.93 or +0.31% to 5,555.65 and the DOW closed DOWN -22.05 or -0.11% to 19,804.72.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 18/21 and 4 flats;                     
  • The mid-day continued negative with an A/DL of 16/23 and 4 flats;
  • The closing bell stayed negative with A/DL of 17/22 and 4 flats;

 

 

Henry’omics:

From this morning’s investor’s letter, “anticipating surprise”

  • Reiterating, “Bruised sector stocks are waiting at the crossroads for a decision of which road to take - a buy to the left or a sell to the right! “Our” universe has been easy pickings as any strength has or will be sold into – eventually. Theirs is NO staying power or sustainability of pricing.”

As I had stated, “The paths of share pricing and upcoming Q4/16 quarterly results will likely provide a focus to the direction for equities.

  • Short-term oversold conditions continue to challenge the stem, cell, gene and regenerative therapy (SCG&RT) sector which have exhibited weak short-term momentum since the first of the year, 2017.

There remains much trepidation with regard to expectation …

  • Talk is cheap and some I-Bank analysis is just … TOO far away from today’s pricing.

Also, it’s up to investors to NOT step-up to some of these repetitive and dilutionary financings … choices NEED to be made!

  • Have investors seen any CEO give up his piece of the small pie to feed the beast of overhead?

 

2017’s problem … the uphill path of share pricing will be bumpy!

 

Indexes, the ebb and flow:

  • The iShares Russell 2000 (IWM) indicated a positive +0.13% in the pre- open and closed UP +0.33%.
  • The iShares NASDAQ Biotechnology (IBB) indicated a positive +0.16% in the pre-open and closed UP +0.83%

 

 

Pre-open indication’s tally:  2 hit (ATHX and ONVO) and 3 miss (AGTC, BLCM and HSGX)

  • Athersys (ATHX) closed DOWN -$0.05 – hit;
  • Applied Genetic Technologies (AGTC) closed DOWN -$0.27 – miss;
  • Bellicum Pharma (BLCM) closed DOWN -$0.15 – miss;
  • Histogenics (HSGX) closed DOWN -$0.06 – miss;
  • Organovo Holdings (ONVO) closed UP +$0.00 – hit;

 

 

Out and about:

Pluristem (PSTI) doing a quick, small and dilutionary overnight offering?

·         PSTI is testing the waters with NO indication of size or dollar pricing of shares offered …

·         Pricing closes DOWN -$0.08 and larger volume closes with 372.1 K shares <3 month average =130.37 K shares>

·         http://www.regmedinvestors.com/articles/9542

 

 

MY idea of the 8 dogs of 2017:

·         BioLife Solutions (BLFS)

·         Brainstorm Cell Therapeutics (BCLI)

·         Capricor (CAPR)

·         Cytori (CYTX)

·         Fibrocell (FCSC)

·         International Stem Cell (ISCO)

·         Northwest Bio (NWBO) and

·         Opexa (OPXA)

 

 

Today’s 5 top $ gainers included:

  • bluebird bio (BLUE) +$2.60 after Tuesday’s-$1.75 after Friday’s +$0.55 after Thursday’s +$1.15 after last Wednesday’s -$3.20;
  • Spark Therapeutics (ONCE) +$1.97 after Tuesday’s -$2.93 after Friday’s -$0.16 after Thursday’s +$1.18 after last Wednesday’s -$5.99;
  • Juno Therapeutics (JUNO) +$1.25 after Tuesday’s -$0.92;
  • Regenxbio (RGNX) +$0.55;
  • Intrexon (XON) +$0.33

 

Today’s 5 largest $ losers of the session were:

  • Aduro (ADRO) -$0.40;
  • Stemline (STML) -$0.40 after Tuesday’s -$0.85 after Friday’s -$0.30;
  • MiMedx (MDXG) -$0.25;
  • AxoGen (AXGN) -$0.20;
  • Applied Genetic Technologies (AGTC) -$0.20

 

Flat:

  • Adverum (ADVM) at $3.05;
  • Brainstorm (BCLI) at $2.71;
  • Organovo (ONVO) at $3.55;
  • Sangamo (SGMO) at $4.10

                                                                                                               

 

The downside trend reflects a pricing trend range of:

  • Wednesday’s decliners ranged from -0.01% <BSTG> to -7.99% <ISCO> in 22 equities;
  • Tuesday’s decliners ranged from -0.10% <OPXA> to -8.53% <CUR> in 38 equities;
  • Monday was a holiday;
  • Friday’s decliners ranged from -0.28% <ONCE> to -16.43% <OPXA> in 14 equities;
  • Thursday’s decliners ranged from -0.34% <QURE> to -8.93% <ISCO> in 24 equities;
  • Last Wednesday’s decliners ranged from -0.38% <CAPR> to -34.76% <IMUC> in 34 equities;

 

The upside shows a pricing trend range of:

  • Wednesday’s gainers ranged from +0.06% <CLLS> to +10.74% <NWBO> in 17 equities;
  • Tuesday’s gainers ranged from +0.33% <KOOL> to +4.07% <MBOT> in 4 equities;
  • Monday was a holiday;
  • Friday’s gainers ranged from +0.22% <KITE> to +11.39% <SGMO> in 27 equities;
  • Thursday’s gainers ranged from +0.31% <JUNO> to +29.93% <OPXA> in 18 equities;
  • Last Wednesday’s gainers ranged from +0.26% <CLBS> to +4.07% <MBOT> in 5 equities;

 

The week so far:

  • Wednesday’s 17 gainers followed Tuesday’s 4, Monday’s holiday, Friday’s 27, Thursday’s 18 and last Wednesday’s 5
  • Wednesday’s 22 decliners followed Tuesday’s 38, Monday’s holiday, Friday’s 14, Thursday’s 24 and last Wednesday’s 34

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Wednesday traded near 12.44;

·         Tuesday traded near 11.8;

·         Monday was a holiday;

·         Friday traded near 11.3;

·         Thursday traded near 12.3 – 9% higher;

·         Last Wednesday traded near 11.6;

 

                                                                                                                                                                               

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.